Christopher James, Managing Director
||Christopher James, M.D. is a Managing Director and Senior Equity Research Analyst focusing on life sciences companies with strong growth potential and novel agents in development for serious diseases including cancer, infectious disease, neurological, inflammatory, metabolic, and cardiovascular diseases. Dr. James was previously a Senior Equity Research Analyst at Rodman & Renshaw and MLV & Co. Prior to joining Brinson Patrick, Dr. James was the Chief Medical Officer & Senior Vice President of Medical Affairs at Retrophin, a biotechnology company focused on developing therapeutics for rare and devastating diseases. While at Retrophin, Dr. James played a pivotal role in the study design and subsequent acceptance of an Investigational New Drug Application (IND) with the Cardiorenal Division of the FDA to initiate a Phase 2 clinical study in a rare kidney disease called focal segmental glomerulosclerosis (FSGS). Chris has prior buy-side experience working at Trivium Capital Management and MSMB Capital Management. Dr. James, who trained in neurological surgery at Cornell-New York Hospital and Memorial Sloan Kettering Cancer Center, brings a unique set of scientific, medical, and clinical skills to his coverage of life sciences companies.Dr. James obtained a Medical Degree from Yale University School of Medicine and a Bachelor of Science in Biology from Cornell University.
||Christopher James, M.D.
Learn more about our Research Offering.
»Contact Brinson Patrick »